|
|
Post by mnholdem on Nov 23, 2019 14:22:01 GMT -5
If I may simplify, rather than get into detailed scenarios, Wall Street generally values most stock based upon actual (current) results in combination with its understanding of whether short- and near-term events will affect a company’s revenue.
In a nutshell, MNKD is valued where it is today because Wall Street doesn’t see any pivotal events on short/near-term horizon.
Frankly, management has only itself to blame for the poor (or lack of) company image and the continued erosion of share price (aka shareholder value).
The closest known events are the TreT clinical trial and the Afrezza Phase 3 pediatric trial and that’s not near-term by any means.
Everything else is entirely speculative because this company does a poor job of communicating its potential to the public. Wall Street will continue to under value this stock until that changes.
|
|
|
|
Post by mnholdem on Nov 23, 2019 13:09:35 GMT -5
“Michael E. Castagna, Pharm.D. has been our Chief Executive Officer and as one of our directors since May 2017. Dr. Castagna was our Chief Commercial Officer from March 2016 until May 2017. From November 2012 until he joined us, Dr. Castagna was at Amgen, Inc., where he initially served as Vice President, Global Lifecycle Management and was most recently Vice President, Global Commercial Lead for Amgen’s Biosimilar Business Unit.”
Based upon His bio, it would appear that Director Hooper was Michael Castagna’s superior, if not his immediate boss:
”Mr. Hooper served as executive vice president of Global Commercial Operations for Amgen Inc. from Oct 2011 until August 2018. During his tenure, he led the transformation of Amgen's commercial organization, placing a relentless focus on putting patients at the center of all the company’s activities. Under his leadership, Amgen grew revenue by 50 percent, launched six new first-in-class medicines for serious diseases, more than doubled the global footprint by expanding into 50 new countries, and established a new biosimilars business.”
I would think that the newly appointed Director is, perhaps, more qualified to assess the CEO’s strengths and weaknesses than any other Board member.
My point? I recommend that shareholders not be toonquick to assume that Mr. Hooper will be supportive of MannKind’s former CCO and current CEO’s performance. He will quickly ascertain facts from fiction.
|
|
|
|
Post by mnholdem on Nov 22, 2019 16:31:21 GMT -5
Gee thanks, mytake... now I’m gonna be humming that song all afternoon. ;-)
|
|
|
|
Post by mnholdem on Nov 21, 2019 19:26:22 GMT -5
Again, to use the Fiasp example, adoption could go much faster. Same drug with a more patient-friendly inhaler.
|
|
|
|
Post by mnholdem on Nov 18, 2019 14:37:39 GMT -5
India will sometimes grant approval based upon FDA data alone.
|
|
|
|
Post by mnholdem on Nov 18, 2019 14:36:11 GMT -5
That’s not what I remember. Cipla applied for an accelerated pathway and was denied. So they simply have to take the normal pathway for approval.
|
|
|
|
Post by mnholdem on Nov 18, 2019 13:27:47 GMT -5
Will Cipla pay for Afrezza to be used in the upcoming trials in India? .... or does Mannkind provide A at no charge for the trials in India? When will Mannkind ship Afrezza to India for the trials? .... as soon as Dec or Jan?
"MannKind will receive a $2.2 million upfront payment from Cipla within 30 days of entering the agreement, with the potential to receive additional regulatory milestone payments, minimum purchase commitment revenue and royalties on Afrezza sales in India."Source: investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-cipla-enter-exclusive-marketing-and-distribution |
|
|
|
Post by mnholdem on Nov 15, 2019 17:10:15 GMT -5
Local coverage but it’s being televised in California where MannKind has targeted some of their sales efforts.
|
|
|
|
Post by mnholdem on Nov 15, 2019 11:43:38 GMT -5
His blood pressure may be up...LOL.
|
|
|
|
Post by mnholdem on Nov 13, 2019 17:06:14 GMT -5
The two best posts of the year are probably the ones holding up MNKD's billboard. I know that Mike C has done a lot to avoid bankruptcy and creating that link with UTHR. Script counts have been growing and soon we will be cash flow positive, even without including revenue for shipping containers to foreign ports. My only problem is ... when will my $$$ be here? But, that's mytakeonit Do you really believe that MC found (linked with) United Therapeutics? UT founder Martine Rothblatt and MannKind founder Alfred Mann go way back...  If by cash flow you have any solid evidence of a strategy than supports revenue growth, let's hear it please. Frankly, after the CEO's revelation about only recently identifying the significance of the "cough" issue as a barrier to patient retention, I'm no longer confident that the pediatric trials will be successful since it's become apparent that MannKind apparently hasn't addressed this. It's a side effect that can be easily fixed, as the VDex President stated, but will MannKind introduce the fix to clinicians conducting the led trials? This issue could offset needles if not adequately addressed. Then where are we? |
|
|
|
Post by mnholdem on Nov 13, 2019 10:09:52 GMT -5
Afrezza is a revolutionary product with the potential to disrupt the diabetes treatment industry. Whether current management wakes up or new management is needed, this product needs to be positioned for what it is. MannKind took a positive step in the creation of the website "inhalemyinsulin". inhalemyinsulin.com/The company now has a forum by which the company can educate WHY an ultra-rapid acting inhaled insulin is revolutionary. Many of the big pharmaceutical companies have similar sites where they can publish relevant articles without violating FDA restrictions related to specific brand names. Why is this relevant? The answer to that question is because there is only ONE ultra-rapid inhaled insulin currently available to patients. Where is Afrezza positioned today? Ask most endocrinologists or primary care physicians and (assuming they've even heard of it) you're likely to hear something like, "Afrezza...isn't it that new inhaled insulin?" MannKind needs to do a MUCH more effective job of positioning its revolutionary insulin with healthcare professionals. The new website can help in that regard but only if management has the vision, the fortitude and the experience needed. In this regard, I am truly hoping that I get what I ask for. |
|
|
|
Post by mnholdem on Nov 13, 2019 9:48:50 GMT -5
Great video from Bill talking about some numbers in New Mexico... This was a much more positive presentation by McCullough which focused more on what VDex is doing right than about what MannKind is doing wrong. I think that Bill's videos about VDex will continue be more effective if he engages shareholders in this manner. |
|
|
|
Post by mnholdem on Nov 11, 2019 12:29:07 GMT -5
As I understand it, the VDex billboards direct people to a specific clinic. I'm not certain that MannKind can do that with theirs but, then again, I've never seen an actual picture of the billboard they designed. |
|
|
|
Post by mnholdem on Nov 8, 2019 17:00:09 GMT -5
IMO, that’s largely because to CEO’s focus is too narrow. The biggest problem with being promoted from middle management is that you remain stuck within one or two compartments.
The job of CEO is much bigger. I’m not talking about micromanaging the entire company. No sir! The CEO job entails having a grasp of how all the pieces fit together and then assembling the team that will carry it out.
Accountability to the CEO’s plan is key. Perhaps this is the reason behind the recent executive bonuses. The plan didn’t stretch the capabilities of the executive team.
|
|
|
|
Post by mnholdem on Nov 8, 2019 16:36:27 GMT -5
There are no children at this table, my friend.
|
|
